Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: A large retrospective study from the Royal Marsden Hospital

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 307-314

  Constantinidou, A ^a   Martin, A ^a   Sharma, B ^a   Johnston, S R D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Metastatic breast cancer; PET CT; Response assessment; Staging

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HORMONAL THERAPY; HUMAN; LIVER DISEASE; LIVER METASTASIS; LUNG DISEASE; LUNG METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED KINGDOM;

EID: 79251546468     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq343     Document Type: Article

References (26)

1. Hoh CK, Hawkins RA, Glaspy JA et al. Cancer detection with whole-body PET using 2-[18F] fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582-589.
2. Avril N, Rosé CA, Schelling M et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18(20): 3495-3502.
3. Veronesi U, De Cicco C, Galimberti VE et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007; 18(3): 473-478.
4. Wahl RL, Siegel BA, Coleman RE et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004; 22: 277-285.
5. Lovrics PJ, Chen V, Coates G et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 2004; 11: 846-853.
6. Gil-Rendo A, Zornoza G, Garcia-Velloso MJ et al. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 2006; 93: 707-712.
7. Goerres GW, Michel SC, Fehr MK et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 2003; 13: 1635-1644.
8. Kim TS, Moon WK, Lee DS et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 2001; 25: 829-834.
9. Kamel EM, Wyss MT, Fehr MK et al. [18F]-fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 2003; 129: 147-153.
10. Lin WY, Tsai SC, Cheng KY et al. Fluorine-18 FDG-PET in detecting local recurrence and distant metastases in breast cancer: Taiwanese experiences. Cancer Invest 2002; 20: 725-729.
11. Lonneux M, Borbath I, Berliere M et al. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 2000; 2: 45-49.
12. Radan L, Ben-Haim S, Bar-Shalom R et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006; 107: 2545-2551.
13. Eubank WB, Mankoff D, Bhattacharya M et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. Am J Roentgenol 2004; 183: 479-486.
14. Gallowitsch HJ, Kresnik E, Gasser J et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003; 38: 250-256.
15. Dose J, Bleckmann C, Bachmann S et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002; 23: 857-864.
16. Hubner KF, Smith GT, Thie JT et al. The potential of F-18-FDG PET in breast cancer: detection of primary lesions, axillary lymph node metastases, or distant metastases. Clin Positron Imaging 2003; 3: 197-205.
17. Bender H, Kirst J, Palmedo H et al. Value of F-18 fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997; 17: 1687-1692.
18. Cook GJ, Houston S, Rubens R et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-3379.
19. Du Y, Cullum I, Illidge TM et al. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007; 25(23): 3440-3447.
20. Ben-Haim S, Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009; 39(6): 408-415.
21. Costelloe CM, Rohren EM, Madewell JE et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 2009; 10(6): 606-614.
22. Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med 2009; 50 (Suppl 1): 55S-63S.
23. Krak N, Boellaard R, Hoekstra OS et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 2005; 32: 294-301.
24. Duch J, Fuster D, Muñoz M et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009; 36(10): 1551-1557.
25. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005; 35: 84-99.
26. Santiago JF, Gonen M, Yeung H et al. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 2006; 50: 61-67.